Diagnostic pathways in acute leukemias: a proposal for a multimodal approach
- 14 February 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 86 (5), 311-327
- https://doi.org/10.1007/s00277-007-0253-2
Abstract
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) each represent a heterogeneous complex of disorders, which result from diverse mechanisms of leukemogenesis. Modern therapeutic concepts are based on individual risk stratification at diagnosis and during follow-up. For some leukemia subtypes such as AML M3/M3v with t(15;17)/PML–RARA or Philadelphia-positive ALL targeted therapy options are available. Thus, optimal therapeutic conditions are based on exact classification of the acute leukemia subtype at diagnosis and are guided by exact and sensitive quantification of minimal residual disease during complete hematologic remission. Today, a multimodal diagnostic approach combining cytomorphology, multiparameter flow cytometry, chromosome banding analysis, accompanied by diverse fluorescence in situ hybridization techniques, and molecular analyses is needed to meet these requirements. As the diagnostic process becomes more demanding with respect to experience of personnel, time, and costs due to the expansion of methods, algorithms, which guide the diagnostic procedure from basic to more specific methods and which lead finally to a synopsis of the respective results, are essential for modern diagnostics and therapeutic concepts.Keywords
This publication has 108 references indexed in Scilit:
- Modern diagnostics in acute leukemiasCritical Reviews in Oncology/Hematology, 2005
- Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical featuresLeukemia, 2005
- Detection of Minimal Residual Disease in Acute Myelogenous LeukemiaActa Haematologica, 2004
- Burkitt's and Burkitt‐like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience*British Journal of Haematology, 2003
- HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosisBlood, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- International standing committee on human cytogenetic nomenclatureCancer Genetics and Cytogenetics, 1996
- Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4EoAnnals of Hematology, 1993
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988